This supports the idea that the dose-response relationship with immunotherapy is not as direct as with chemotherapy.5 The survival benefits and adverse effects of this treatment at 2 mg/kg IV Q3W are well documented in the literature.6-9 In the 5-year analysis of KEYNOTE-024, a trial of pembrolizumab monotherapy for metastatic NSCLC with PD-L1 TPS ≥ 50%, median overall survival (OS) was 26.3 months and median progression-free survival (PFS) was 7.7 months. The gene discussed is CD274; the disease is non-small cell lung carcinoma.